Jeff Yass’s PharmaCyte Biotech PMCB Stock Holding History

Jeff Yass’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.5K	Buy	+44,853	New	+$33.8K	﹤0.01%	12930
2025 Q3	–	Sell	-27,606	Closed	-$30.4K	–	13566
2025 Q2	$30.4K	Buy	27,606 +9,200	+50%	+$10.3K	﹤0.01%	12249
2025 Q1	$23K	Sell	18,406 -16,075	-47%	-$26.1K	﹤0.01%	12076
2024 Q4	$53.4K	Sell	34,481 -747	-2%	-$1.29K	﹤0.01%	11646
2024 Q3	$67.3K	Sell	35,228 -19,606	-36%	-$36.5K	﹤0.01%	11254
2024 Q2	$107K	Buy	54,834 +13,646	+33%	+$29.4K	﹤0.01%	10981
2024 Q1	$97.6K	Buy	41,188 +19,160	+87%	+$41.5K	﹤0.01%	11232
2023 Q4	$47.6K	Buy	+22,028	New	+$47.7K	﹤0.01%	11733
2023 Q2	–	Sell	-106,886	Closed	-$311K	–	12889
2023 Q1	$311K	Buy	+106,886	New	+$314K	﹤0.01%	9646
2022 Q4	–	Sell	-16,624	Closed	-$47.6K	–	13392
2022 Q3	$40K	Sell	16,624 -61,985	-79%	-$157K	﹤0.01%	12334
2022 Q2	$178K	Buy	78,609 +50,547	+180%	+$110K	﹤0.01%	10810
2022 Q1	$65K	Buy	+28,062	New	+$62.3K	﹤0.01%	12173

Other funds holding PMCB

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Jeff Yass's PMCB Position: Q2 2026 in Review

Jeff Yass opened a new position in PharmaCyte Biotech (PMCB) in Q2 2026: 44,853 shares worth $34.5K. The stake represents ﹤0.01% of the portfolio and ranks #12930 among its holdings. This is a return to the name: Jeff Yass previously reported a position in PMCB as recently as Q2 2025.

Jeff Yass first reported a position in PMCB in Q1 2022 and has held it in 12 quarters since. The position peaked at $311K in Q1 2023. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

Jeff Yass held 44,853 shares of PharmaCyte Biotech worth $34.5K as of Q2 2026.
PharmaCyte Biotech was a new Jeff Yass position in Q2 2026.
PharmaCyte Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12930 holding.
Jeff Yass first reported a position in PharmaCyte Biotech in Q1 2022 and has held it in 12 quarters since.
Jeff Yass's PharmaCyte Biotech position peaked at $311K in Q1 2023.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.